2-methoxy-N-(3-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide | 1425927-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-methoxy-N-(3-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide
• 英文别名: 2-methoxy-N-(3-methyl-2-oxo-1H-quinolin-6-yl)benzenesulfonamide
• CAS: 1425927-02-1
• 化学式: C₁₇H₁₆N₂O₄S
• 分子量: 344.391
• InChiKey: ZJOXYTXHQNVVJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯-5-硝基苯甲醛 在 吡啶 、 sodium hydrogen sulfate 、 palladium 10% on activated carbon 、 氢气 作用下， 以 N-甲基吡咯烷酮 、 5,5-dimethyl-1,3-cyclohexadiene 、 溶剂黄146 为溶剂， 20.0~225.0 ℃ 、446.08 kPa 条件下， 反应 21.25h， 生成 2-methoxy-N-(3-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide
  参考文献：
  名称：

  Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins

  摘要：

  使用亲和捕获在人类细胞核提取物中展示了基于PFI-1的BET溴结构域探针的选择性。

  DOI：

  10.1039/c4md00259h

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE BROMODOMAINE
  申请人：PFIZER

  公开号：WO2013027168A1

  公开（公告）日：2013-02-28

  Disclosed are compounds of Formula (I): (I) which are useful as bromodomain inhibitors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are bromodomain-dependent are also disclosed. Methods for preparing and using these compounds are further described.

  揭示了以下式（I）的化合物：（I），这些化合物可用作溴结构域抑制剂。还揭示了含有式（I）化合物的药物组合物，以及利用式（I）化合物治疗依赖于溴结构域的疾病或紊乱的用途。进一步描述了制备和使用这些化合物的方法。
• BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Coferon, Inc.

  公开号：US20140243286A1

  公开（公告）日：2014-08-28

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本文介绍了一种单体，当在水介质中与一个、两个、三个或更多其他单体接触时，能够形成生物上有用的多聚体。在其中一方面，这种单体可以在水介质中（例如在体内）与另一个单体结合形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团和连接元素的连接元素。在水介质中，这些考虑到的单体可以通过每个连接元素连接在一起，因此可以同时调节一个或多个生物分子，例如调节蛋白质或不同蛋白质上的两个或更多结合结构域。
• Phosphatase Binding Compounds and Methods of Using Same
  申请人：Yale University

  公开号：US20200268897A1

  公开（公告）日：2020-08-27

  The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.
• [EN] BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE BRODOMAINES CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2013033270A2

  公开（公告）日：2013-03-07

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.
• [EN] METHODS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND/OR THERAPY MONITORING<br/>[FR] PROCÉDÉS POUR LE TRAITEMENT DE LA BRONCHO-PNEUMOPATHIE CHRONIQUE OBSTRUCTIVE ET/OU DE SURVEILLANCE DU TRAITEMENT
  申请人：HARVARD COLLEGE

  公开号：WO2016168565A1

  公开（公告）日：2016-10-20

  Described herein are methods for diagnosis and treatment of chronic obstructive pulmonary disease (COPD) exacerbation and/or therapy monitoring based in part on the level of macrophage colony-stimulating factor (M-CSF) expression and/or activity. Methods for diagnosis and treatment of COPD patients using novel molecular signature(s) are also provided. Methods for identifying subjects with COPD exacerbations who are more likely to be responsive to and benefit from a therapy that targets virus-induced exacerbations or non-infective COPD exacerbations are also described herein.